News
President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price negotiations; Vinay Prasad to take the helm at the FDA’s Center for Biologics ...
The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...
Axios on MSN5d
Vinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
Not Vinay Prasad. The new top regulator of vaccines and gene therapies at the Food and Drug Administration has never shied ...
From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...
MedPage Today on MSN5dOpinion
Vinay Prasad Speaks to CBER Staff: Which Prasad Showed Up?The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluation and Research, after Peter Marks was ...
In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...
Vinay Prasad, a skeptic of mainstream medicine, is now a top FDA official. Change is coming for some drugmakers, one way or ...
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a professor at the University of California-San ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback